Q1 Earnings Forecast for DNLI Issued By William Blair

Key Points

• William Blair analysts predict Denali Therapeutics Inc. will report a Q1 2026 EPS of ($0.86), with a full-year estimate of ($3.56) EPS for 2026.
• The company recently posted ($0.72) EPS for Q2 2025, exceeding expectations, and currently has an average rating of "Buy" with a price target around $33.50.
• Insider selling indicates a 1.20% decrease in ownership for one executive, while institutional investors now hold 92.92% of Denali's stock.

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Research analysts at William Blair issued their Q1 2026 EPS estimates for shares of Denali Therapeutics in a research note issued on Monday, October 13th. William Blair analyst M. Minter anticipates that the company will post earnings per share of ($0.86) for the quarter. The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.71) per share. William Blair also issued estimates for Denali Therapeutics' Q2 2026 earnings at ($0.90) EPS, Q3 2026 earnings at ($0.90) EPS, Q4 2026 earnings at ($0.90) EPS, FY2026 earnings at ($3.56) EPS, FY2027 earnings at ($2.86) EPS and FY2028 earnings at ($0.49) EPS.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its earnings results on Monday, August 11th. The company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.02. During the same quarter last year, the firm posted ($0.59) EPS.

Several other research analysts also recently weighed in on the stock. Cantor Fitzgerald reissued an "overweight" rating on shares of Denali Therapeutics in a research report on Monday, September 8th. Morgan Stanley dropped their target price on shares of Denali Therapeutics from $33.00 to $30.00 and set an "overweight" rating on the stock in a research report on Monday, August 18th. Weiss Ratings reissued a "sell (d-)" rating on shares of Denali Therapeutics in a report on Wednesday, October 8th. Finally, TD Cowen raised shares of Denali Therapeutics to a "strong-buy" rating in a report on Monday, July 28th. Three analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Denali Therapeutics currently has an average rating of "Buy" and an average price target of $33.50.

Denali Therapeutics Stock Up 7.2%

Denali Therapeutics stock opened at $16.31 on Thursday. The company's 50-day moving average price is $14.67 and its two-hundred day moving average price is $14.27. The stock has a market cap of $2.38 billion, a price-to-earnings ratio of -5.82 and a beta of 1.30. The company has a current ratio of 10.27, a quick ratio of 10.27 and a debt-to-equity ratio of 0.01. Denali Therapeutics has a 52 week low of $10.57 and a 52 week high of $33.33.

Insider Buying and Selling at Denali Therapeutics

In related news, insider Alexander O. Schuth sold 2,937 shares of the business's stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $13.58, for a total value of $39,884.46. Following the completion of the transaction, the insider owned 242,346 shares of the company's stock, valued at $3,291,058.68. The trade was a 1.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Carole Ho sold 2,937 shares of the business's stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total value of $39,884.46. Following the completion of the transaction, the insider directly owned 217,391 shares of the company's stock, valued at approximately $2,952,169.78. This trade represents a 1.33% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 6,680 shares of company stock valued at $91,569 in the last ninety days. Insiders own 12.50% of the company's stock.

Institutional Trading of Denali Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Marex Group plc bought a new stake in Denali Therapeutics in the second quarter valued at approximately $3,665,000. State of Wyoming purchased a new stake in Denali Therapeutics in the 2nd quarter valued at $29,000. Hudson Bay Capital Management LP raised its position in Denali Therapeutics by 16.0% in the 2nd quarter. Hudson Bay Capital Management LP now owns 290,000 shares of the company's stock valued at $4,057,000 after buying an additional 40,000 shares during the last quarter. Caxton Associates LLP bought a new position in Denali Therapeutics in the 2nd quarter valued at $199,000. Finally, Headlands Technologies LLC bought a new position in Denali Therapeutics in the 2nd quarter valued at $26,000. 92.92% of the stock is currently owned by institutional investors.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.